Gregory Warren Discusses Measuring Value and Scaling Up Value-Based Contracting

,

Thus far, value-based contracts for prescription drugs has not been transformative because of the scalability challenge for payers, explained Gregory Warren, FSA, FCA, MAAA, partner and consulting actuary with Axene Health Partners.

Thus far, value-based contracts for prescription drugs has not been transformative because of the scalability challenge for payers, explained Gregory Warren, FSA, FCA, MAAA, partner and consulting actuary with Axene Health Partners.

Warren was the keynote speaker on day 2 of the 2022 PBMI Annual National Conference in Orlando, Florida.